Inhibitors of YAP/TAZ activity, including newly developed TEAD autopalmitoylation inhibitors, hold significant promise as antineoplastic agents in multiple cancer types, including HNSCC. Here, YAP1 is linked to head and neck squamous cell carcinoma.